Looks good. Cotempla hitting the market later this year and PDUFA for NT-0201 on September 15, 2017.
Commercial Highlights for Adzenys XR-ODT™
•Prescription Growth Continues into Second Year on Market: Adzenys XR- ODT continued to perform well and the cumulative total number of prescriptions filled for Adzenys XR-ODT, as reported by IMS, were 41,954 for the three months ended June 30, 2017, an increase of 29.9% over the 32,296 for the three months ended March 31, 2017. As of July 21, 2017, the cumulative total number of prescriptions filled for Adzenys XR-ODT since its launch in May 2016, as reported by IMS, were 114,112.
•New to Brand Market Share Continues to Grow Rapidly: As of June 2017, Adzenys XR-ODT has become the preferred alternative dosage treatment for ADHD, as more patients (35%) started on Adzenys XR-ODT than any other alternative dosage form product.
•Number of Prescribers Continues to Grow Throughout the US: The number of prescribers of Adzenys XR-ODT continued to grow since launch, and as of June 30, 2017, 7,405 health care providers had written prescriptions for the product. As of July 14, 2017, that number had increased to 7,699.
•Doctors are Switching Their Patients Over to Adzenys XR-ODT: Patients switching from another ADHD medication accounted for approximately 74% of all new Adzenys XR-ODT prescriptions, as reported by IMS, as of the week ended July 21, 2017.
•Product Appeal for All Patient Types: As of the week ended July 21, 2017, as reported by IMS, 59% of all new Adzenys XR-ODT prescriptions were for pediatric patients and 41% were for adult patients, indicating a broad appeal of Adzenys XR-ODT in all patient types.
Select Financial Results for the Second Quarter Ended June 30, 2017
•Total product revenues were $4.9 million for the three months ended June 30, 2017, compared to $1.5 million for the same period in 2016. This includes product revenue associated with dispensed patient prescriptions of Adzenys XR-ODT of $4.2 million and $0.7 million in net sales for generic Tussionex.
•Cost of goods sold for the three months ended June 30, 2017, was $2.6 million, compared to $2.3 million for the same period of 2016. The increase was primarily due to product costs mainly due to sales of Adzenys XR-ODT.
•The Company reported a gross profit of $2.3 million for the three months ended June 30, 2017, compared to a gross loss of $0.9 million for the same period in 2016.
•Research and development expenses of $3.7 million for the three months ended June 30, 2017 were unchanged from the same period in 2016.
•Selling and marketing expenses were $11.7 million for the three months ended June 30, 2017, compared to $16.2 million for the same period in 2016. The decreased expense was due to a decrease in advertising agency fees and other costs due to expenses in 2016 in anticipation of and for the Adzenys XR-ODT launch.
•General and administrative expenses for the three months ended June 30, 2017 were $3.3 million, compared to $3.2 million for the same period in 2016.
•The Company reported a net loss of $18.7 million for the three months ended June 30, 2017, compared to a net loss of $26.5 million for the same period in 2016.
•The Company reported net loss per share of $0.83 for the three months ended June 30, 2017, compared to a net loss per share of $1.65 for the same period in 2016.
•At June 30, 2017, the Company held $78.6 million in cash and cash equivalents and short-term investments.
